...
首页> 外文期刊>Clinical drug investigation >A Fixed Combination of Cinnarizine/Dimenhydrinate for the Treatment of Patients with Acute Vertigo Due to Vestibular Disorders A Randomized, Reference-Controlled Clinical Study
【24h】

A Fixed Combination of Cinnarizine/Dimenhydrinate for the Treatment of Patients with Acute Vertigo Due to Vestibular Disorders A Randomized, Reference-Controlled Clinical Study

机译:固定的桂皮嗪/二羟海明酸酯联合治疗因前庭疾病而导致的急性眩晕患者随机对照研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background and objective: Vestibular dysfunction commonly leads to - often severe - vertigo symptoms. The objective of this study was to compare the antivertiginous efficacy and tolerability of a fixed combination of cinnarizine/ dimenhydrinate with those of betahistine in patients with acute vertigo due to vestibular disorders.Methods: Sixty-six patients experiencing acute vertigo attacks participated in this prospective, double-blind, three-centre, comparative study. Patients who assessed at least one vertigo symptom as being of medium intensity (>2) on a 5-point visual analogue scale (VAS; from 0 = no symptoms to 4 = very severe symptoms) were randomly allocated to treatment with the fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg three times daily or betahistine 12 mg three times daily for 4 weeks. The primary efficacy endpoint was change in mean vertigo score, as determined by patients' assessments of 12 individual vertigo symptoms on the 5-point VAS after 4 weeks of treatment.
机译:背景和目的:前庭功能障碍通常导致-常常是严重的-眩晕症状。这项研究的目的是比较固定剂量的肉桂酸/苯海拉明与倍他司汀的固定组合对前庭疾病引起的急性眩晕的抗眩晕效果和耐受性。方法:66名经历了急性眩晕发作的患者参加了这项前瞻性研究,双盲,三中心,比较研究。在5点视觉模拟量表(VAS;从0 =无症状到4 =非常严重的症状)上,评估至少一种眩晕症状为中等强度(> 2)的患者被随机分配至固定剂量的桂利嗪20毫克和苯海明酸盐40毫克,每日3次,或倍他司汀12毫克,每日3次,共4周。主要疗效终点是平均眩晕评分的变化,这由患者对治疗4周后在5点VAS上对12种个体眩晕症状的评估确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号